Survey Monocef-O/PVSBP/26-27MCI Registration NumberFULL NAME (As in your Pancard)EmailPhone/MobileCityStateSpecialityBank DetailsAccount Holder NameA/c NumberIFSC CodeUpload Cancelled Cheque (Max Size - 2 MB)Choose File Pancard NumberUpload Pancard Details (Max Size - 2 MB)Choose File SURVEILLANCE STUDY ON THERAPEUTIC CHALLENGES OFPOST-VIRAL SECONDARY BACTERIAL PNEUMONIA MCQ QUESTIONNAIRE1. In your clinical experience, what is the most common bacterial pathogen responsible for secondary bacterial pneumonia following a viral respiratory illness in adult Indian patients? Mycoplasma pneumoniae Streptococcus pneumoniae Pseudomonas aeruginosa Legionella pneumophila2. A 52-year-old male presents with productive cough, fever, and breathlessness 7 days after recovering from influenza. HRCT shows bilateral patchy consolidation. Which of the following best describes this clinical scenario? Primary viral pneumonia progressing to ARDS B Post-viral secondary bacterial pneumonia (PVSBP) C Aspiration pneumonia unrelated to viral illness D Pulmonary tuberculosis reactivation3. Which of the following antibiotic classes covers both typical (S. pneumoniae, H. influenzae) and atypical organisms (Mycoplasma, Chlamydophila) — the two major pathogen groups in post-viral CAP — when used in combination? Beta-lactam + Macrolide combination B Aminoglycoside monotherapy C Fluoroquinolone + Vancomycin D Metronidazole + Clindamycin4. Regarding oral antibiotic selection for moderate post-viral secondary bacterial pneumonia managed in the outpatient or step-down setting, which property is MOST clinically relevant? High urine concentration High oral bioavailability with lung tissue penetration Renal dose adjustment not required Once-weekly dosing schedule5. A 45-year-old post-COVID patient develops secondary bacterial pneumonia with a sputum culture showing beta-lactamase-producing Haemophilus influenzae. Which oral antibiotic would be MOST appropriate? Ampicillin 500mg TDS Cefpodoxime Proxetil 200mg BD Co-trimoxazole DS BD Erythromycin 500mg QID6. In the context of antibiotic stewardship for post-viral bacterial pneumonia, which statement best justifies the use of Cefpodoxime Proxetil 200mg over broader-spectrum intravenous agents in clinically stable patients? IV antibiotics are always superior regardless of clinical stability Oral 3rd-gen cephalosporins allow effective outpatient therapy, reducing hospitalization and nosocomial risks Cefpodoxime has activity against MRSA, making IV therapy unnecessary Oral therapy is only suitable for mild viral URTI, not bacterial pneumonia7. Which of the following correctly describes the spectrum of Cefpodoxime Proxetil 200mg relevant to post-viral secondary bacterial pneumonia? Active against MRSA and Pseudomonas aeruginosa only Active against S. pneumoniae, H. influenzae (including beta-lactamase producers), M. catarrhalis, and Enterobacteriaceae Active only against anaerobes and gram-negative enteric organisms Active only against Mycoplasma and Legionella species8. What is the recommended duration of antibiotic therapy for uncomplicated post-viral secondary bacterial pneumonia in an immunocompetent adult responding to treatment? 3 days 5-7 days 14-21 days Duration is irrelevant; therapy continues until symptom resolution only9. A 60-year-old diabetic patient with post-influenza pneumonia has a penicillin allergy (rash, no anaphylaxis). Which of the following oral agents is appropriate? Amoxicillin-Clavulanate (avoid — same beta-lactam ring class concern for non-anaphylactic allergy) Cefpodoxime Proxetil 200mg BD (cross-reactivity with penicillin is very low; safe in non-anaphylactic allergy) Clindamycin (limited gram-negative respiratory coverage) Metronidazole 400mg TDS (no activity against respiratory pathogens)10. From a pharmacoeconomic and patient adherence perspective, which factor makes Cefpodoxime Proxetil 200mg a preferred empiric choice for treating post-viral secondary bacterial pneumonia in the Indian primary care setting? It requires therapeutic drug monitoring (TDM) for dosing Twice-daily oral dosing, proven efficacy against key pathogens, oral bioavailability, and cost-effectiveness enabling adherence It is only available as an intravenous formulation in India It requires co-administration with probenecid to achieve therapeutic levels I have read and agree to the Terms and Conditions .Submit Form